乳腺癌患者CA-15-3、CEA临床应用价值探讨

目的探讨CA-15-3、CEA在乳腺癌患者中的应用价值。方法应用电化学发光技术对62例乳腺癌患者、22例乳腺良性疾病患者及20例正常对照者血清CA-15-3、CEA水平进行了检测并比较。结果CA-15-3、CEA水平在乳腺癌Ⅰ、Ⅱ、Ⅲ期与乳腺良性疾病组及正常对照组无显著性差异(P>0.05),但在乳腺癌临床分期中有逐渐升高趋势,在Ⅳ期乳腺癌中表达明显增高(P<0.05;P<0.01),在远处转移患者表达明显高于单纯淋巴结转移患者,有淋巴结转移患者表达明显高于无淋巴结转移患者(P均<0.01),在不同组织来源乳腺癌患者中表达无明显差异(P>0.05)。结论CA-15-3、CEA并非乳腺癌早期诊断的理想标志物,但其表达与肿瘤临床分期、淋巴结转移及远处转移密切相关,在预测乳腺癌转移、复发及监测疗效、判断预后等方面具有重要临床应用价值,在乳腺癌中表达无组织细胞特异性。

The clinical value of CA-15-3 and CEA in breast cancer

Objective To evaluate the clinical value of CA-15-3 and CEA in breast cancer. Methods With ECLusys1010 electrochemical luminescence instrument, the level of CA-15-3,CEA in 62 breast cancer patients,22 benign breast disease patients and 20 normal people (as control) were detected. Results The expression of CA-15-3 and CEA in breast cancer at Ⅰ,Ⅱ,Ⅲ stage, benign breast disease group and normal control group had no significant difference(P>0.05), while the numerical value had increasing trend, and their expression in breast cancer at Ⅳ stage was significantly higher than that of the other groups(P<0.01;P<0.05), and the expression in group of having organ metastasis was significantly higher than that of having simply lymphoma metastasis group and non-lymphoma metastasis group(P<0.01); the level of CA-15-3 and CEA had no significant difference in patients with different tissue origin breast cancer(P>0.05). Conclusion CA-15-3 and CEA are not ideal tumor marker in diagnosing early breast cancer, but their expression are correlated significantly with tumor staging, organ metastasis and lymphaden metastasis; they have important value in forecasting tumor metastasis, recurrence and monitoring curative effect and judging prognosis, their expression had no tissue and cell specificity.